| Pharmaceutical Information |
| Drug Name |
Velaglucerase alfa |
| Drug ID |
BADD_D02343 |
| Description |
Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease. |
| Indications and Usage |
Velaglucerase alfa is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease. |
| Marketing Status |
approved; investigational |
| ATC Code |
A16AB10 |
| DrugBank ID |
DB06720
|
| KEGG ID |
D09029
|
| MeSH ID |
Not Available
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0G5ET
|
| NDC Product Code |
54092-701 |
| UNII |
23HYE36B0I
|
| Synonyms |
Not Available |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
884604-91-5 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
